First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe
Health Affairs · 2025
DOI: 10.1377/hlthaff.2024.01072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2025. Verfasst von Jihye Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jihye Han (jihan@bwh.harvard.edu), Brigham and Women's Hospital and Harvard University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Arnold Ventures and the Commonwealth Fund.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Jihye Han (jihan@bwh.harvard.edu), Brigham and Women's Hospital and Harvard University, Boston, Massachusetts.
- Aaron S. Kesselheim, Brigham and Women's Hospital and Harvard University.
Förderung
- Arnold Ventures and the Commonwealth Fund
Zitieren
APA
Han, J., & Kesselheim, A. S. (2025). First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe. Health Affairs. https://doi.org/10.1377/hlthaff.2024.01072
Vancouver
Han J, Kesselheim AS. First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe. Health Affairs. 2025. doi:10.1377/hlthaff.2024.01072
BibTeX
@article{Han2025,
author = {Han, Jihye and Kesselheim, Aaron S},
title = {First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe},
journal = {Health Affairs},
year = {2025},
doi = {10.1377/hlthaff.2024.01072}
}
EUVIMED